Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Defining lesional, perilesional and unaffected skin in hidradenitis suppurativa: proposed recommendations for clinical trials and translational research studies.

Frew JW, Navrazhina K, Byrd AS, Garg A, Ingram JR, Kirby JS, Lowes MA, Naik H, Piguet V, Prens EP.

Br J Dermatol. 2019 Jul 3. doi: 10.1111/bjd.18309. [Epub ahead of print] No abstract available.

PMID:
31269228
2.

High prevalence of hidradenitis suppurativa in patients with perianal fistula.

Ardon CB, Molenaar C, van Straalen KR, Scholtes VC, Prens EP, van der Zee HH.

Int J Colorectal Dis. 2019 Jul;34(7):1337-1339. doi: 10.1007/s00384-019-03313-2. Epub 2019 May 16.

PMID:
31093736
3.

Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.

Jemec GBE, Okun MM, Forman SB, Gulliver WPF, Prens EP, Mrowietz U, Armstrong AW, Geng Z, Gu Y, Williams DA, Teixeira HD, Kimball AB.

Br J Dermatol. 2019 Nov;181(5):967-975. doi: 10.1111/bjd.17919. Epub 2019 Aug 14.

PMID:
30916379
4.

Virulent Staphylococcus lugdunensis with limited genetic diversity in hidradenitis suppurativa lesions.

Ardon CB, Prens EP, Tkadlec J, Fuursted K, Abourayale S, Jemec GBE, Jenssen H.

J Eur Acad Dermatol Venereol. 2019 Jun;33(6):e248-e250. doi: 10.1111/jdv.15523. Epub 2019 Mar 15. No abstract available.

PMID:
30801776
5.

The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study.

Vossen ARJV, Ardon CB, van der Zee HH, Lubberts E, Prens EP.

Br J Dermatol. 2019 Aug;181(2):314-323. doi: 10.1111/bjd.17641. Epub 2019 Apr 12.

6.

Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model.

Vossen ARJV, van der Zee HH, Prens EP.

Front Immunol. 2018 Dec 14;9:2965. doi: 10.3389/fimmu.2018.02965. eCollection 2018.

7.

Highlights of the updated Dutch evidence- and consensus-based guideline on psoriasis 2017.

van der Kraaij GE, Balak DMW, Busard CI, van Cranenburgh OD, Chung Y, Driessen RJB, de Groot M, de Jong EMGJ, Kemperman PMJH, de Kort WJA, Karsch SA, Lamberts A, Lecluse LLA, van Lümig PPM, Menting SP, Prens EP, van den Reek JMPA, Seyger MMB, Thio HB, Veldkamp WR, Wakkee M, Nast A, Jacobs A, Rosumeck S, Spuls Chair PI.

Br J Dermatol. 2019 Jan;180(1):31-42. doi: 10.1111/bjd.17198. No abstract available.

8.

High prevalence of clinical spondyloarthritis features in patients with hidradenitis suppurativa.

Rondags A, van Straalen KR, Arends S, van der Zee HH, Prens EP, Spoorenberg A, Horváth B.

J Am Acad Dermatol. 2019 Feb;80(2):551-554.e1. doi: 10.1016/j.jaad.2018.06.028. Epub 2018 Dec 14. No abstract available.

PMID:
30554892
9.

Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported quality of life and objective disease severity assessment.

Rondags A, van Straalen KR, van Hasselt JR, Janse IC, Ardon CB, Vossen ARJV, Prens EP, van der Zee HH, Horváth B.

Br J Dermatol. 2019 May;180(5):1214-1220. doi: 10.1111/bjd.17508. Epub 2019 Feb 25.

PMID:
30512186
10.

Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial.

Vossen ARJV, van Doorn MBA, van der Zee HH, Prens EP.

J Am Acad Dermatol. 2019 Jan;80(1):80-88. doi: 10.1016/j.jaad.2018.06.046. Epub 2018 Jul 3.

PMID:
30482392
11.

Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers.

Vossen ARJV, van der Zee HH, Davelaar N, Mus AMC, van Doorn MBA, Prens EP.

J Eur Acad Dermatol Venereol. 2019 Apr;33(4):761-765. doi: 10.1111/jdv.15354. Epub 2018 Dec 10.

12.

Novel cytokine and chemokine markers of hidradenitis suppurativa reflect chronic inflammation and itch.

Vossen ARJV, van der Zee HH, Tsoi LC, Xing X, Devalaraja M, Gudjonsson JE, Prens EP.

Allergy. 2019 Mar;74(3):631-634. doi: 10.1111/all.13665. Epub 2018 Dec 10. No abstract available.

13.

Apocrine Gland-Rich Skin Has a Non-Inflammatory IL-17-Related Immune Milieu, that Turns to Inflammatory IL-17-Mediated Disease in Hidradenitis Suppurativa.

Jenei A, Dajnoki Z, Medgyesi B, Gáspár K, Béke G, Kinyó Á, Méhes G, Hendrik Z, Dinya T, Törőcsik D, Zouboulis CC, Prens EP, Bíró T, Szegedi A, Kapitány A.

J Invest Dermatol. 2019 Apr;139(4):964-968. doi: 10.1016/j.jid.2018.10.020. Epub 2018 Oct 31. No abstract available.

14.

Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group.

Zouboulis CC, Bechara FG, Dickinson-Blok JL, Gulliver W, Horváth B, Hughes R, Kimball AB, Kirby B, Martorell A, Podda M, Prens EP, Ring HC, Tzellos T, van der Zee HH, van Straalen KR, Vossen ARJV, Jemec GBE.

J Eur Acad Dermatol Venereol. 2019 Jan;33(1):19-31. doi: 10.1111/jdv.15233. Epub 2018 Oct 23.

15.

Hurley III Hidradenitis Suppurativa Has an Aggressive Disease Course.

Vanlaerhoven AMJD, Ardon CB, van Straalen KR, Vossen ARJV, Prens EP, van der Zee HH.

Dermatology. 2018;234(5-6):232-233. doi: 10.1159/000491547. Epub 2018 Aug 27. No abstract available.

16.

Biofilm production and antibiotic susceptibility of Staphylococcus epidermidis strains from Hidradenitis Suppurativa lesions.

Ardon CB, Prens EP, Fuursted K, Ejaz RN, Shailes J, Jenssen H, Jemec GBE.

J Eur Acad Dermatol Venereol. 2019 Jan;33(1):170-177. doi: 10.1111/jdv.15183. Epub 2018 Aug 7.

PMID:
30022542
17.

Laser-Haarentfernung verändert den Krankheitsverlauf bei leichter Hidradenitis suppurativa.

Vossen ARJV, van der Zee HH, Terian M, van Doorn MBA, Prens EP.

J Dtsch Dermatol Ges. 2018 Jul;16(7):901-903. doi: 10.1111/ddg.13563_g. No abstract available.

PMID:
29989379
18.

Current and future treatment of hidradenitis suppurativa.

van Straalen KR, Schneider-Burrus S, Prens EP.

Br J Dermatol. 2018 Jul 7. doi: 10.1111/bjd.16768. [Epub ahead of print] Review.

PMID:
29981245
19.

Aggravation of mild axillary hidradenitis suppurativa by microwave ablation: Results of a randomized intrapatient-controlled trial.

Vossen ARJV, van Huijkelom MAPC, Nijsten TEC, Bakker EWP, van der Zee HH, van Doorn MBA, Prens EP.

J Am Acad Dermatol. 2019 Mar;80(3):777-779. doi: 10.1016/j.jaad.2018.06.032. Epub 2018 Jun 22. No abstract available.

PMID:
29940205
20.

Laser hair removal alters the disease course in mild hidradenitis suppurativa.

Vossen ARJV, van der Zee HH, Terian M, van Doorn MBA, Prens EP.

J Dtsch Dermatol Ges. 2018 Jul;16(7):901-903. doi: 10.1111/ddg.13563. Epub 2018 Jun 22. No abstract available.

PMID:
29933519
21.

Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.

Zouboulis CC, Okun MM, Prens EP, Gniadecki R, Foley PA, Lynde C, Weisman J, Gu Y, Williams DA, Jemec GBE.

J Am Acad Dermatol. 2019 Jan;80(1):60-69.e2. doi: 10.1016/j.jaad.2018.05.040. Epub 2018 Jun 1.

PMID:
29860040
22.

Comprehensive, Multimodal Characterization of an Imiquimod-Induced Human Skin Inflammation Model for Drug Development.

van der Kolk T, Assil S, Rijneveld R, Klaassen ES, Feiss G, Florencia E, Prens EP, Burggraaf J, Moerland M, Rissmann R, van Doorn MBA.

Clin Transl Sci. 2018 Nov;11(6):607-615. doi: 10.1111/cts.12563. Epub 2018 Jul 3.

23.

Complement Activation in Inflammatory Skin Diseases.

Giang J, Seelen MAJ, van Doorn MBA, Rissmann R, Prens EP, Damman J.

Front Immunol. 2018 Apr 16;9:639. doi: 10.3389/fimmu.2018.00639. eCollection 2018. Review.

24.

Poor interrater reliability of hidradenitis suppurativa phenotypes.

van Straalen KR, Verhagen T, Horváth B, Ardon C, Vossen ARJV, Driessen R, Boer J, Rondags ALV, Prens EP, van der Zee HH.

J Am Acad Dermatol. 2018 Sep;79(3):577-578. doi: 10.1016/j.jaad.2018.02.048. Epub 2018 Mar 2. No abstract available.

PMID:
29486212
25.

Hidradenitis suppurativa treated with wide excision and second intention healing: a meaningful local cure rate after 253 procedures.

Deckers IE, Dahi Y, van der Zee HH, Prens EP.

J Eur Acad Dermatol Venereol. 2018 Mar;32(3):459-462. doi: 10.1111/jdv.14770. Epub 2018 Jan 17.

PMID:
29265421
26.

Phototherapy of Psoriasis, a Chronic Inflammatory Skin Disease.

Rácz E, Prens EP.

Adv Exp Med Biol. 2017;996:287-294. doi: 10.1007/978-3-319-56017-5_24. Review.

PMID:
29124709
27.

Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II.

Thorlacius L, Garg A, Ingram JR, Villumsen B, Theut Riis P, Gottlieb AB, Merola JF, Dellavalle R, Ardon C, Baba R, Bechara FG, Cohen AD, Daham N, Davis M, Emtestam L, Fernández-Peñas P, Filippelli M, Gibbons A, Grant T, Guilbault S, Gulliver S, Harris C, Harvent C, Houston K, Kirby JS, Matusiak L, Mehdizadeh A, Mojica T, Okun M, Orgill D, Pallack L, Parks-Miller A, Prens EP, Randell S, Rogers C, Rosen CF, Choon SE, van der Zee HH, Christensen R, Jemec GBE.

Br J Dermatol. 2018 Mar;178(3):715-721. doi: 10.1111/bjd.16093. Epub 2018 Feb 1.

28.

Sequence variants in hidradenitis suppurativa: in search of the pathogenic mechanisms.

Vossen ARJV, van der Zee HH, Prens EP.

Br J Dermatol. 2017 Oct;177(4):895-896. doi: 10.1111/bjd.15812. No abstract available.

PMID:
29052868
29.

Intrapatient Variability in the Pharmacokinetics of Etanercept Maintenance Treatment.

van Bezooijen JS, Schreurs MWJ, Koch BCP, Velthuis HT, van Doorn MBA, Prens EP, van Gelder T.

Ther Drug Monit. 2017 Aug;39(4):333-338. doi: 10.1097/FTD.0000000000000384.

PMID:
28691952
30.

Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice.

Cohen AD, Wu JJ, Puig L, Chimenti S, Vender R, Rajagopalan M, Romiti R, de la Cruz C, Skov L, Zachariae C, Young HS, Foley P, van der Walt JM, Naldi L, Prens EP, Blauvelt A.

Br J Dermatol. 2017 Dec;177(6):1495-1502. doi: 10.1111/bjd.15756. Epub 2017 Nov 27. Review.

PMID:
28646580
31.

Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.

Zouboulis CC, Tzellos T, Kyrgidis A, Jemec GBE, Bechara FG, Giamarellos-Bourboulis EJ, Ingram JR, Kanni T, Karagiannidis I, Martorell A, Matusiak Ł, Pinter A, Prens EP, Presser D, Schneider-Burrus S, von Stebut E, Szepietowski JC, van der Zee HH, Wilden SM, Sabat R; European Hidradenitis Suppurativa Foundation Investigator Group.

Br J Dermatol. 2017 Nov;177(5):1401-1409. doi: 10.1111/bjd.15748. Epub 2017 Oct 30.

PMID:
28636793
32.

Prolongation of Biologic Dosing Intervals in Patients With Stable Psoriasis: A Feasibility Study.

van Bezooijen JS, van Doorn MBA, Schreurs MWJ, Koch BCP, Te Velthuis H, Prens EP, van Gelder T.

Ther Drug Monit. 2017 Aug;39(4):379-386. doi: 10.1097/FTD.0000000000000420.

PMID:
28570371
33.

Assessing Pruritus in Hidradenitis Suppurativa: A Cross-Sectional Study.

Vossen ARJV, Schoenmakers A, van Straalen KR, Prens EP, van der Zee HH.

Am J Clin Dermatol. 2017 Oct;18(5):687-695. doi: 10.1007/s40257-017-0280-2.

34.

Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial.

Busard CI, Menting SP, van Bezooijen JS, van den Reek JM, Hutten BA, Prens EP, de Jong EM, van Doorn MB, Spuls PI.

Trials. 2017 Feb 2;18(1):52. doi: 10.1186/s13063-017-1777-y. Erratum in: Trials. 2017 Mar 7;18(1):113.

35.

Non-invasive anaesthetic methods for dermatological laser procedures: a systematic review.

Greveling K, Prens EP, Liu L, van Doorn MBA.

J Eur Acad Dermatol Venereol. 2017 Jul;31(7):1096-1110. doi: 10.1111/jdv.14130. Epub 2017 Feb 8. Review.

PMID:
28107576
36.

Surgical Denervation in the Imiquimod-Induced Psoriasiform Mouse Model.

Onderdijk AJ, Hekking-Weijma IM, Florencia EF, Prens EP.

Methods Mol Biol. 2017;1559:75-81. doi: 10.1007/978-1-4939-6786-5_6.

PMID:
28063038
37.

Menses and pregnancy affect symptoms in hidradenitis suppurativa: A cross-sectional study.

Vossen AR, van Straalen KR, Prens EP, van der Zee HH.

J Am Acad Dermatol. 2017 Jan;76(1):155-156. doi: 10.1016/j.jaad.2016.07.024. No abstract available.

PMID:
27986138
38.

IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis.

Balak DM, van Doorn MB, Arbeit RD, Rijneveld R, Klaassen E, Sullivan T, Brevard J, Thio HB, Prens EP, Burggraaf J, Rissmann R.

Clin Immunol. 2017 Jan;174:63-72. doi: 10.1016/j.clim.2016.09.015. Epub 2016 Nov 20.

PMID:
27876460
39.

Inflammatory bowel disease is associated with hidradenitis suppurativa: Results from a multicenter cross-sectional study.

Deckers IE, Benhadou F, Koldijk MJ, Del Marmol V, Horváth B, Boer J, van der Zee HH, Prens EP.

J Am Acad Dermatol. 2017 Jan;76(1):49-53. doi: 10.1016/j.jaad.2016.08.031. Epub 2016 Oct 25.

PMID:
27793450
40.

Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): A case series.

Riis PT, Boer J, Prens EP, Saunte DM, Deckers IE, Emtestam L, Sartorius K, Jemec GB.

J Am Acad Dermatol. 2016 Dec;75(6):1151-1155. doi: 10.1016/j.jaad.2016.06.049. Epub 2016 Sep 28.

PMID:
27692735
41.

Accelerated wound healing after wide excisions in Hidradenitis Suppurativa using autologous split-thickness skin grafting and platelet-rich plasma.

Vossen AR, van der Zee HH, Prens EP.

Int Wound J. 2017 Jun;14(3):583-586. doi: 10.1111/iwj.12673. Epub 2016 Sep 9. No abstract available.

PMID:
27611792
42.

Hidradenitis suppurativa is not associated with the metabolic syndrome based on body type: A cross-sectional study.

Vossen ARJV, van der Zee HH, Onderdijk AJ, Boer J, Prens EP.

J Dermatol. 2017 Feb;44(2):154-159. doi: 10.1111/1346-8138.13572. Epub 2016 Sep 8.

PMID:
27608328
43.

Combination Therapy of Etanercept and Fumarates versus Etanercept Monotherapy in Psoriasis: A Randomized Exploratory Study.

van Bezooijen JS, Balak DM, van Doorn MB, Looman CW, Schreurs MW, Koch BC, van Gelder T, Prens EP.

Dermatology. 2016;232(4):407-14. doi: 10.1159/000448135. Epub 2016 Sep 1.

44.

Lentigo maligna - anatomic location as a potential risk factor for recurrences after non-surgical treatment.

Greveling K, van der Klok T, van Doorn MB, Noordhoek Hegt V, Prens EP.

J Eur Acad Dermatol Venereol. 2017 Mar;31(3):450-454. doi: 10.1111/jdv.13941. Epub 2016 Sep 19.

45.

The Association between Hidradenitis Suppurativa and Crohn's Disease: in Search of the Missing Pathogenic Link.

van der Zee HH, Horvath B, Jemec GBE, Prens EP.

J Invest Dermatol. 2016 Sep;136(9):1747-1748. doi: 10.1016/j.jid.2016.05.102. Epub 2016 Jul 20.

46.

Hidradenitis suppurativa: development of outcome measure instruments.

van der Zee HH, Vossen RJ, Prens EP.

Br J Dermatol. 2016 Aug;175(2):242. doi: 10.1111/bjd.14673. No abstract available.

PMID:
27535596
47.

Hurley Staging Refined: A Proposal by the Dutch Hidradenitis Suppurativa Expert Group.

Horváth B, Janse IC, Blok JL, Driessen RJ, Boer J, Mekkes JR, Prens EP, van der Zee HH.

Acta Derm Venereol. 2017 Mar 10;97(3):412-413. doi: 10.2340/00015555-2513. No abstract available.

48.

Sexual health and quality of life are impaired in hidradenitis suppurativa: a multicentre cross-sectional study.

Janse IC, Deckers IE, van der Maten AD, Evers AWM, Boer J, van der Zee HH, Prens EP, Horváth B.

Br J Dermatol. 2017 Apr;176(4):1042-1047. doi: 10.1111/bjd.14975. Epub 2017 Feb 24.

PMID:
27534591
49.

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.

Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, Armstrong AW, Kerdel F, Gold MH, Forman SB, Korman NJ, Giamarellos-Bourboulis EJ, Crowley JJ, Lynde C, Reguiai Z, Prens EP, Alwawi E, Mostafa NM, Pinsky B, Sundaram M, Gu Y, Carlson DM, Jemec GB.

N Engl J Med. 2016 Aug 4;375(5):422-34. doi: 10.1056/NEJMoa1504370.

50.

Allergic contact dermatitis caused by topical sirolimus used as an adjuvant for laser treatment of port wine stains.

Greveling K, Kunkeler AC, Prens EP, van Doorn MB.

Contact Dermatitis. 2016 Sep;75(3):184-5. doi: 10.1111/cod.12589. No abstract available.

PMID:
27480514

Supplemental Content

Loading ...
Support Center